Activation of melanocytes in idiopathic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: Preliminary analysis of a randomized, split-body, single blinded, placebo controlled clinical trial
To the Editor: This letter presents a preliminary analysis of the first 8 patients who have completed a randomized clinical trial for idiopathic guttate hypomelanosis (IGH) treatment that was approved by the respective ethics committee and registered in the ClinicalTrials.gov database under identifier NCT02904564. The rationale for this study was the preliminary histologic analysis of IGH spots in which we observed varying degrees of papillary dermis fibrosis. 1 Fulton et al 2 described the repigmentation of hypopigmented scars arising from different etiologies after mechanical removal of dermal fibrosis. The formulated hypothesis was that IGH repigmentation could occur if the underlying dermal fibrosis were removed. Instead of mechanically removing this fibrosis, as described by Fulton et al, 2 we attempted to remove or reduce it by delivering medication with antifibrotic properties. Because of its low cost, injectable 5-fluorouracil (5-FU) was the drug of choice, which has been used for scar treatment since 1990. 3 We named the drug delivery technique used in this clinical trial MMP (the Portuguese acronym for microinfusão de medicamentos na pele [ie, microinfusion of drugs into the skin]). 4 This technique drew inspiration from the ancient art of tattooing. In MMP, the tattoo machine's needles convey the medication contained in the sterile needle cartridge into the skin (Fig 1, B and C ) -ie, the microneedling and injection processes occur simultaneously (Fig 1, A) . Needling depth is gradually adjusted until mild pinpoint bleeding is achieved (Fig 1, D) , which is an indication that the dermis has been reached.
The intervention was done using a Cheyenne tattoo machine by MT.DERM (Berlin, Germany), the only equipment of the sort approved by the Brazilian Health Agency (ANVISA) for medical use. Two dermatologists, blinded to the randomization, determined the limb present the best therapeutic outcome by clinical analysis (Fig 2, A-D) . Statistical analysis was performed using Antera 3D 5 (Miravex, Dublin, Partial repigmentation of placebo-treated lesions may have been caused by collagen remodeling induced by simple microneedling of the papillary dermis. We believe that 5-FU MMP treatment may be beneficial in treating IGH. Even though no adverse effects were observed in MMP-treated patients, the safety and efficacy of this 5-FU drug delivery method needs to be proven by means of additional studies.
Tattooing is an ancient technique under public domain done mainly by tattoo artists, we have chosen to copyright the acronym MMP in Brazil and the United States and grant free use exclusively to dermatologists who are members of the Brazilian Society of Dermatology and equivalent entities around the world. Dr Arbache's commercial involvement in this investigation was required in order to obtain approval of the equipment for medical use under Brazilian health legislation (as enforced by Agência Nacional de Vigilância Sanit aria) and to render this investigation acceptable for the relevant ethics committee. We hereby inform that the clinical results described and documented herein can be achieved using any available tattoo machine. Dr Arbache is a member of a staff that trains Brazilian dermatologists in the use of this technique. The machine, its cartridges, and the medicines used in this study were supplied by Traderm (São Jos e dos Campos, Brazil). Hidradenitis suppurativa burden of disease tool: Pilot testing of a diseasespecific quality of life questionnaire
To the Editor: Hidradenitis suppurativa (HS) is a chronic inflammatory condition affecting intertriginous areas of the body that dramatically impairs quality of life (QoL) and has a substantial psychosocial burden. 1,2 Full remission of HS is rare, making improvements in QoL a critical goal of therapy. Currently, when investigating the impact of HS, we are limited to generic QoL questionnaires, none of which are specific for HS. We propose a diseasespecific tool that would better capture the unique burden of disease caused by HS, which is necessary to determine the impact of therapeutic interventions in clinical trials and in the clinical setting.
We used both consensus expert opinion from 8 medical dermatologists and patient input to develop the Hidradenitis Suppurativa Burden of Disease (HSBOD) tool (Supplemental Material; available at http://www.jaad.org). The HSBOD is a 19-item selfadministered visual analog scale (VAS) questionnaire designed to provide a more nuanced and accurate understanding of the overall burden of disease among patients with HS. Questions in this novel tool include a 10-cm VAS ranging from 0 (no complaints) to 10 (worst complaints). VASs have been validated, making survey completion rapid and easy while yielding more precise responses; however, the HSBOD requires abstract thinking, which may be difficult for some patients. 3, 4 We compared HSBOD tool performance to the commonly used, nonedisease-specific Dermatology Life Quality Index (DLQI). HSBOD questions were divided into 5 domains: ''symptoms and feelings,'' (questions 1-9 and 17) and impact upon ''daily activities,'' (questions 10 and 13) ''leisure,'' (questions 11, 13, and 14) ''work/school,'' (questions 12, 18, and 19), and ''personal relationships'' (questions 6-9, 15, and 16). Twenty-nine patients (none of whom participated in tool development) with HS who were diagnosed by a Board-certified dermatologist completed both surveys without assistance.
The reliability, or the degree to which the HSBOD produces stable results, was assessed by Cronbach alpha. 5 Cronbach alpha of 0.936 for this study indicates good internal consistency within the HSBOD. The median HSBOD score was 5.5 of 10 and the median DLQI was 13 of 30. Spearman rho was calculated as a measure of the strength of the rank correlation between HSBOD and DLQI. Individuals' HSBOD scores were plotted against corresponding DLQI scores for the overall summary score and subscales (Fig 1) . Questions on the HSBOD corresponding to ''symptoms and feelings'' ( ¼ 0.681, P \.001), ''leisure'' ( ¼ 0.661, P \.001), and ''daily activities'' ( ¼ 0.598, P \ .001) had a strong correlation to the corresponding DLQI subscales. HSBOD questions corresponding to ''personal relationships'' ( ¼ 0.419, P ¼ .024) and ''work/ school'' ( ¼ 0.310, P ¼ .101) had a moderate correlation with the corresponding DLQI questions, although the ''work/school'' domain did not achieve statistical significance. The lack of a strong correlation between the HSBOD and DLQI for ''personal relationships'' and ''work/school'' may reflect that the HSBOD has several questions designed to specifically investigate issues in HS, while the DLQI has fewer generic questions for all skin disorders. We feel this lack of correlation could represent shortcomings of the DLQI in fully capturing the many facets of HS contributing to the burden of disease.
Although our study is limited by the small sample size and likely increased disease severity among patients in a tertiary care referral center, the HSBOD questionnaire shows internal reliability and correlates strongly ( ¼ 0.604, P \ .001) with a validated nonspecific skin QoL tool (the DLQI). Future studies with broader data collection should confirm item selection, validity, and reliability of HSBOD considering the lower item-scale correlations for a subset of the 19 items.
We thank the patients who have graciously accepted to complete the surveys. Without their participation, this study would not have been possible.
